David Stark - Teva Pharmaceutical Executive Vice President, Chief Legal Officer
| TEVA Stock | ILA 7,798 171.00 2.15% |
President
Mr. David Matthew Stark serves as Executive Vice President, Chief Legal Officer of Teva Pharmaceutical Industries Limited. Mr. Stark became Executive Vice President, Chief Legal Officer in November 2017. From November 2016 to November 2017, he served as Group Executive Vice President, Chief Legal Officer. From 2014 to 2015, Mr. Stark was Senior Vice President and General Counsel, Global Specialty Medicines. Since joining Teva in 2002, Mr. Stark served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr Gallagher LLP between 1998 and 2002, Chadbourne Parke between 1997 and 1998 and Haight, Gardner, Poor Havens between 1994 and 1997 since 2016.
| Age | 54 |
| Tenure | 9 years |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
David Stark Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Stark against Teva Pharmaceutical stock is an integral part of due diligence when investing in Teva Pharmaceutical. David Stark insider activity provides valuable insight into whether Teva Pharmaceutical is net buyers or sellers over its current business cycle. Note, Teva Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teva Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Stark over a year ago Exercise or conversion by David Stark of 18430 shares of Teva Pharma subject to Rule 16b-3 |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Shelly Gordon | Elbit Systems | 58 | |
| Avi Mizrachi | Elbit Systems | 60 | |
| Oren Shirazi | Tower Semiconductor | 53 | |
| Itzhak Edrei | Tower Semiconductor | 58 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| David Temin | Elbit Systems | 67 | |
| Marco Racanelli | Tower Semiconductor | 56 | |
| Amir Nachlieli | Bezeq Israeli Telecommunication | 56 | |
| Yuval Ramon | Elbit Systems | 57 | |
| Zeev Gofer | Elbit Systems | 66 | |
| Ilan Rabinovich | Tower Semiconductor | 61 | |
| Yossi Netzer | Tower Semiconductor | 59 | |
| Yehudit Grisaro | El Al Israel | 61 | |
| Nati Somekh | Tower Semiconductor | 48 | |
| Gary Saunders | Tower Semiconductor | 54 | |
| Avi Strum | Tower Semiconductor | 61 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Ilan Pacholder | Elbit Systems | 64 | |
| Elad Aharonson | Elbit Systems | 45 | |
| Yehoshua Yehuda | Elbit Systems | 55 | |
| Edgar Maimon | Elbit Systems | 64 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Janet Vergis, Independent Director | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Abbas Hussain, Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Perry Nisen, Independent Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Andrew Weil, Chief Accounting Officer | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.